Osteoprotegerin and receptor activator of nuclear factor‐κB ligand system in the early post‐operative period of liver transplantation

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Clinical Transplantation

• Publication date

  2006-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1399-0012.2006.00497.xPMID 16824158
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Posttransplant bone disease

  2007cited by this paper
• AGA technical review on osteoporosis in hepatic disorders.

  2003cited by this paper
• Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation.

  2003cited by this paper
• Osteoporosis in liver diseases and after liver transplantation.

  2003cited by this paper
• Osteoprotegerin and its correlations with new markers of bone formation and bone resorption in kidney transplant recipients.

  2003cited by this paper
• RANK-L and RANK: T cells, bone loss, and mammalian evolution.

  2002cited by this paper
• Clonal endothelial cells produce humoral factors that inhibit osteoclast-like cell formation in vitro.

  2002cited by this paper
• Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status.

  2002cited by this paper
• Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells.

  2001cited by this paper
• Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A

  2001cited by this paper
• Osteoprotegerin levels before and after renal transplantation.

  2001cited by this paper
• Receptor Activator of NF-κB and Osteoprotegerin Expression by Human Microvascular Endothelial Cells, Regulation by Inflammatory Cytokines, and Role in Human Osteoclastogenesis*

  2001cited by this paper
• Bone versus immune system.

  2000cited by this paper
• Interactions between immune and bone cells: new insights with many remaining questions.

  2000cited by this paper
• The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption

  2000cited by this paper
• RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism.

  2000cited by this paper
• Osteoprotegerin Is an αvβ3-induced, NF-κB-dependent Survival Factor for Endothelial Cells*

  2000cited by this paper
• Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells.

  2000cited by this paper
• Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

  1999cited by this paper
• Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.

  1999cited by this paper
• Mechanism of Bone Loss After Liver Transplantation: A Histomorphometric Analysis

  1999cited by this paper
• Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.

  1999cited by this paper
• Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

  1999cited by this paper
• OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

  1999cited by this paper
• Osteoporosis after organ transplantation.

  1998cited by this paper
• Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

  1998cited by this paper
• TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption

  1998cited by this paper
• Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

  1998cited by this paper
• Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.

  1998cited by this paper
• Serum soluble selectins in patients undergoing cardiopulmonary bypass. Relationship with circulating blood cells and inflammation‐related cytokines

  1997cited by this paper
• Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells.

  1997cited by this paper
• A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

  1997cited by this paper
• TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells*

  1997cited by this paper
• Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

  1997cited by this paper
• Regulation of Osteoclast Function

  1997cited by this paper
• Advances in bone biology: the osteoclast.

  1996cited by this paper
• Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine.

  1996cited by this paper
• Could the piggyback operation in liver transplantation be routinely used?

  1994cited by this paper
• Osteoporosis and bone morbidity in cardiac transplant recipients.

  1994cited by this paper
• The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo.

  1994cited by this paper
• Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization.

  1994cited by this paper
• Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis.

  1994cited by this paper
• Prevention of orthotopic liver allograft rejection in rats with a short-term brequinar sodium therapy. Analysis of intragraft cytokine gene expression.

  1994cited by this paper
• Perspectives: Posttransplantation bone disease

  1992cited by this paper
• Modulation of osteoclast differentiation.

  1992cited by this paper
• Modulation of osteoclast differentiation [published erratum appears in Endocr Rev 1992 May;13(2):191]

  1992cited by this paper
• Posttransplantation bone disease.

  1992cited by this paper
• Comparison of the effects of FK506 and cyclosporine on bone mineral metabolism in the rat. A pilot study.

  1991cited by this paper
• Loss of vertebral bone density in heart transplant patients.

  1991cited by this paper
• Bone loss after liver transplantation

  1991cited by this paper
• Rapid loss of vertebral mineral density after renal transplantation.

  1991cited by this paper
• Combined treatment with cyclosporin A and cortisone acetate minimizes the adverse bone effects of either agent alone

  1990cited by this paper
• T-lymphocyte-antigen interactions in transplant rejection.

  1990cited by this paper
• Reduced bone mineral density in men and women with allogeneic bone marrow transplantation.

  1990cited by this paper
• Circulating osteocalcin in primary biliary cirrhosis following liver transplantation and during treatment with ciclosporin.

  1990cited by this paper
• The effect of cyclosporin A administration and its withdrawal on bone mineral metabolism in the rat.

  1989cited by this paper
• Potential protection by cyclosporin against glucocorticoid effects on bone.

  1989cited by this paper

• Changes in Serum Bone Metabolism Markers after Living Donor Liver Transplantation (LDLT) and Their Association with Fracture Occurrences

  2023cites this paper
• High risk of osteoporosis and fracture following solid organ transplantation: a population-based study

  2023cites this paper
• Osteoporosis in organ transplant patients

  2021cites this paper
• Receptor activator of the NFκB ligand system protects renal function during experimental renal ischemia-reperfusion in mice.

  2020cites this paper
• Transplantation Osteoporosis

  2020cites this paper
• Hepatic Osteodystrophy—Molecular Mechanisms Proposed to Favor Its Development

  2019cites this paper
• Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society.

  2019cites this paper
• Osteoporosis in Organ Transplant Patients

  2016cites this paper
• Mechanism and Treatment Strategy of Osteoporosis after Transplantation

  2015cites this paper
• The role of insulin-like growth factor 1, receptor activator for nuclear factor κB ligand - osteoprotegerin system, interleukin 6 and 1β in post-transplantation bone metabolic disease in childhood.

  2013cites this paper
• Receptor activator of nuclear factor‐κB ligand (RANKL) protects against hepatic ischemia/reperfusion injury in mice

  2012cites this paper
• Osteoporosis after solid organ transplantation.

  2012cites this paper
• Post-Transplantation Bone Disease

  2012cites this paper
• Osteoporosis After Transplantation

  2012cites this paper
• Post-transplantation osteoporosis Osteoporose pós-transplante

  2010cites this paper
• Activation of adenosine A2A receptor attenuates inflammatory response in a rat model of small-for-size liver transplantation.

  2010cites this paper
• Post-transplantation osteoporosis.

  2010cites this paper
• Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: Are they of any help?

  2010cites this paper
• Current World Literature

  2007cites this paper
• Post-transplantation osteoporosis.

  2007cites this paper
• Osteoporose pós-transplante

  2006cites this paper